Tools   Select Another Resource Report Type

http://ki.se/ki/jsp/polopoly.jsp?d=29358&a=31598&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. Project creating a DNA biobank from persons admitted to the neurointensive care unit of the Karolinska University Hospital to study possible genetic influences in traumatic brain injuries (TBI). Serum and cerebrospinal fluid sampled during the subacute phase are also collected. Samples were collected prospectively from clinically well characterized patients to allow for studies of association between candidate genes and clinical outcome parameters or biomarkers for relevant disease processes. The aim is to collect samples from 200-400 individuals. Samples will be collected from TBI patients at up to three different occasions. At first sampling, whole blood, serum and liquor will be collected and at the second and third occasions only serum and liquor.

Proper citation: KI Biobank - TBI (RRID:SCR_005897) Copy   

•   Source: SciCrunch Registry
  

http://ki.se/en/imm/eims-an-epidemiological-investigation-of-risk-factors-for-multiple-sclerosis

A multi-center population based epidemiological investigation of risk factors for Multiple Sclerosis (MS), where lifestyle- and environmental factors are examined systematically with concurrent genetic information. Newly diagnosed cases of MS in a geographically defined population and randomly chosen controls are identified and asked to answer a questionnaire on lifestyle, previous exposures at work, home and during spare time activities. For both cases and controls blood samples are taken for analysis of putative risk genes since environmental exposures probably contributes to disease only in individuals with certain genotypes. Exposures of interest are different sociodemographic factors, smoking, sunlight exposure, oral contraceptives / hormonal factors, butyrophilin (a milk protein), vaccinations, infections, atopic disease, organic solvents, mineral oils and a number of different psychosocial factors, such as critical lifetime events. Data from more than 1600 cases and 3200 controls are currently collected. (August 2014) The intention is to continue with the data collection over several years in order to analyse how genes and environment interact. The study is a collaboration between different institutions at Karolinska Institutet and neurological centers from 38 different hospitals in Sweden. Sample types * EDTA whole blood * DNA * Plasma * Serum

Proper citation: KI Biobank - EIMS (RRID:SCR_005898) Copy   

•   Source: SciCrunch Registry
  

http://ki.se/en/imm/gems-genes-and-environment-in-multiple-sclerosis

The study subjects invited to participate is chosen from the Swedish national Multiple Sclerosis registry and will number around 10 000 individuals to be included during two to three years. The same number of matched controls will also be included in the study. A pilot study with around 100 participants was performed during 2009, and the large scale study started in November 2009. Multiple sclerosis (MS) is a neurological disease that affects the central nervous system. It affects young people and the debut age is between 20 and 40 years. The disease comes with exacerbations but further on leads to disability. The incidence in Sweden is around 5 per 100 000 per year and the prevalence is 125 per 100 000 inhabitants. In total there are estimated around 13000 cases in Sweden and today 9000 of them are registered in the Swedish National Multiple Sclerosis register. Sample types * EDTA whole blood * DNA * Plasma Number of sample donors: 5592 (June 2010)

Proper citation: KI Biobank - GEMS (RRID:SCR_005893) Copy   

•   Source: SciCrunch Registry
  

http://www.geisinger.org/research/centers_departments/genomics/mycode/mycode.html

By collecting and analyzing blood samples from Geisinger''s large patient population, MyCode will help unlock the mysteries of some of the most devastating and debilitating diseases. Blood samples are obtained from patients of certain Geisinger specialty clinics to study specific conditions, such as obesity and cardiovascular disease, and also from patients of Geisinger primary care clinics to provide a representative sample of the regional population. More than 60,000 samples from over 23,000 Geisinger patients have been collected so far, and sample collection is ongoing. MyCode researchers use the blood samples to study the genetic causes of diseases and certain disease-related molecular mediators. Knowledge gained from these studies will allow researchers to pursue innovative approaches to disease prevention, diagnosis and treatment. To be of value for Genomic Medicine research, bio-banked samples must be connected to clinical data: MyCode allows genetic and molecular data about the samples to be connected to medical data in a way that protects patient identity. When a patient agrees to participate in MyCode, blood samples for the MyCode Project are collected during blood draws ordered as part of the patient''s routine medical care. After the sample is drawn and labeled, a staff member from the Weis Center for Research transports the blood to the Geisinger Clinic Genomics Core (GCGC) where it is processed for storage. At this stage, all personal identification markers are removed and the samples are assigned a randomly-selected identification number. A secure key is maintained that allows approved researchers to connect the samples to the clinical data for genomic studies in a way that ensures confidentiality of the information. To maintain confidentiality of MyCode data the code linking the research numbers and the electronic health records are kept in a password-protected files accessible only to MyCode team members. Additionally, all results generated from the samples are reported as a group so that individuals are not identified. The samples are stored indefinitely.

Proper citation: Geisinger Biobank (RRID:SCR_005652) Copy   

•   Source: SciCrunch Registry
  

http://ki.se/ki/jsp/polopoly.jsp?d=29350&a=36311&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. Study to investigate symptoms of Attention Deficit Hyperactivity Disorder (ADHD) according to DSM-IV in adults with special focus on attention deficit. Information is used from the Swedish Twin study of Adults: genes and Environment (STAGE) from the Swedish Twin Registry. ADHD-discordant and concordant samples of pairs of twins for ADHD are selected from STAGE for studies of brain structure and function with Functional Magnetic Resonance Imaging (fMRI).

Proper citation: KI Biobank STAGE-ADHD (RRID:SCR_005921) Copy   

•   Source: SciCrunch Registry
  

http://www.pathology.med.ohio-state.edu/HTRN/apc/default.asp

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. The Adenoma Polyp Tissue Bank (APTB) receives whole blood from patients enrolled in the Prevention of Sporadic Colorectal Adenomas with Celecoxib clinical trial. We have reached our accrual on blood submissions, so we will no longer be receiving blood specimens The objectives of this trial are as follows: A. To determine the efficacy and safety of celecoxib versus placebo in preventing the occurrence of newly detected colorectal adenomas in subjects at increased risk for colorectal carcinoma. In addition to incidence, other established risk factors will be evaluated for their association with occurrence of new colorectal adenomas, including cancer family history and adenoma size, histopathologic grade, multiplicity and location. Primary assessment of treatment efficacy will be the reduction in the number of subjects with adenomas at colonoscopy after Year 1 and Year 3 of study drug use. Secondary assessments of treatment efficacy will be 1) the number of adenomas 2) the histopathologic grade of adenomas and 3) the size of adenomas, also measured after one year and three years of study drug use. These factors will be incorporated into a risk model for predicting adenoma occurrence and response to celecoxib. B. To determine the efficacy of celecoxib versus placebo in modulating one or more of a panel of biomarkers for colorectal cancer at the cellular and molecular level sampled in a subset of subjects at selective sites at baseline and after Year 1 and Year 3 of study drug use. These biomarkers will include measurements of aberrant crypt foci (ACF), proliferation (index and crypt distribution), apoptosis (index and crypt distribution), COX expression and activity. If modulation of one or more mucosal biomarkers occur, we will explore whether it correlates with the development of incident colorectal neoplasia (adenomas/carcinomas), thereby attempting to validate the surrogacy of that biomarker. C. To develop a specimen bank. Serum and white blood cells are isolated from whole blood and adenoma tissue blocks and slides are banked. Banked specimens will become available for use in correlative science studies at a later point. This project began in 1999 and will be extended through 2006. The lead principal investigator is Monica M. Bertagnolli, MD, Brigham and Women''s Hospital, Boston, MA, and the APTB Director is Scott Jewell, Ph.D., Department of Pathology, The Ohio State University. The APTB is supported by the NIH, NCI Division of Cancer Prevention, in connection with the Strang Cancer Prevention Center, Cornell University, New York., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Adenoma Polyp Tissue Bank (RRID:SCR_005366) Copy   

•   Source: SciCrunch Registry
  

http://www.ahcdc.ca/index.php/national-studies/blood-borne-pathogens

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. To develop a method to look for known and emerging blood borne diseases, a secure bank of samples has been established to test for known blood borne infectious agents and genetic changes causing or modifying the clotting disease, and to be available for testing for newly discovered viruses and clotting gene changes as they are found. The objectives of this project are: * To collect blood samples for a sample bank of plasma, DNA, and RNA to screen for known and emerging blood borne diseases. * To identify the mutation leading to each consenting patient''s bleeding disorder, and to characterize other known and yet to be discovered genes that affect blood coagulation. * To collect encoded, non-nominal data into a central database from an electronic chart known as CHARMS, which is currently kept in each hemophilia clinic in Canada to correlate with results from 1 and 2.

Proper citation: Blood Borne Pathogens Laboratory (RRID:SCR_004707) Copy   

•   Source: SciCrunch Registry
  

http://dtp.nci.nih.gov/branches/btb/services.html

National Cancer Institute Biorepositories provides information on the tumor repository, animal production program, and access to other NIH Repositories. A catalog of in vitro cell lines, transplantable animal and human tumors and microarrays, including ordering information, is available. In the Animal Production Program, rodents are supplied to Federal Institutions and to grantees/contractors with a current OLAW Assurance on file. Requests from international entities seeking rodent strains solely available from the NCI Animal Production Program must have an OLAW Assurance or current AAALACi accreditation and will be evaluated on a case-by-case basis. In general, the rodents are supplied to the following: * Researchers at NCI-Frederick * NIH on-campus laboratories * NIH/NCI funded research contracts * NIH/NCI funded grantees * Other government agencies To meet the above needs, animal production contracts plus quality control contracts are used. The animal production contracts are used to propagate the NIH sublines of the strains. Many of the strains produced are not available commercially and the NCI program is the sole source of several lines.

Proper citation: National Cancer Institute Biorepositories (RRID:SCR_004789) Copy   

•   Source: SciCrunch Registry
  

http://ki.se/ki/jsp/polopoly.jsp?d=29328&a=31530&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. Longitudinal Assessment of Clinical Course and BIOmarkers in severe Chronic AIRway Disease (BIOAIR) is a study within the European Network For Understanding Mechanisms Of Severe Asthma (ENFUMOSA). BIOAIR study involves studies of severe asthma. The 10% of all asthmatics who have the most difficult disease has a 5-year survival in level with severe cancer diseases, as well as account for half of the costs to society of asthma. Mechanisms for the development of severe asthma, however, is unknown. BIOAIR the project characterizes clinical Phenotype and biomarkers in a study involving 12 centers in nine European countries. In a longitudinal study comparing severe asthmatics with mild asthmatics and patients with COPD (Chronic obstructive pulmonary disease). Clinical data and medicine consumption are collected daily in over a year with the help of modern IT technology. Blood tests, urine samples, upphostningsprover and bronkialbiopsier are collected repeatedly and tested for a wide range of possible pathogenetic factors, including genotype.

Proper citation: BIOAIR - BIOmarkers in severe Chronic AIRway Disease (RRID:SCR_006007) Copy   

•   Source: SciCrunch Registry
  

http://ki.se/ki/jsp/polopoly.jsp?d=29328&a=31532&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. Longitudinal studies that consist of more than 40 000 subjects that have been followed since 1986 to be used in studies on how hereditary factors influence the development and progression of Chronic Obstructive Pulmonary Disease (COPD). Its overall objective to find ??tg??rdbara determinants of especially asthma and COPD but also allergy and OSAS (obstructive sleep apnea syndrome). Research is carried out in two huvudforskningslinger; population studies among adults of asthma, allergies, COPD, chronic bronchitis and OSAS. The second main line of longitudinal studies on asthma and allergies among schoolchildren with measurement of incidence, remission and morbidity. The study followed annually all 3500 schoolchildren since 1996 when they went in first and second class in Kiruna, Lulea and Pitea. In addition to questionnaire studies contained in methods, as well as in the adult studies, mainly respiratory function, BMI, skin prick test and clinical interview. Main fragestallningen of risk factors for incident asthma and allergy.

Proper citation: OLIN - Obstructive Lung disease in Northern Sweden (RRID:SCR_006009) Copy   

•   Source: SciCrunch Registry
  

http://ki.se/ki/jsp/polopoly.jsp?d=29354&a=36389&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented September 2, 2016. The Swedish twin registry has recently examined all twins in Sweden born between 1959-1985. 25,000 individuals participated in the study. The twins had to implement a Web-based survey on the Internet or a telephone interview where we had to answer questions about, among other things, about the diseases they have, or have had, behaviors, eating and drinking habits, smoking habits, etc. The aim of the study is to extend the information in the Swedish twin registry. Our goal with twin studies are, inter alia, to study the relative importance of the heritage and environment for the emergence of various diseases. The responses from the study is currently the basis for a number of analyses regarding how inheritance and environment affects disease and tobacco habits. Currently third follow-up STAGE where 10,000 twins that had previously taken part are contacted again. The purpose of alteplase randomized controlled trials is to follow up the same individuals one year after the first and second questionnaire replies were received to see if anything has changed. The issues we are interested in the follow-up to include changes in general health, working and living situation, your weight, smoking habits, etc. Study Results The results we have so far come to and which we can present here are figures on the prevalence of certain diseases. The figures give a rough estimate of the incidence of these diseases will look for all individuals, born in Sweden in 1959-1985. The figures are based on the questions on the questionnaire which the twins themselves had to answer whether they have or have had various diseases.

Proper citation: KI Biobank - STAGE (RRID:SCR_006004) Copy   

•   Source: SciCrunch Registry
  

http://ki.se/en/meb/the-child-and-adolescent-twin-study-in-sweden-catss

Data and biomaterial from a study investigating how both genetic and environmental effects influence health and behavior in children and adolescents. In this study parents to all Swedish twins turning 9 or 12 years are asked to complete a telephone interview concerning the health and behavior of their twins. The interview screens for several different health (e.g., asthma, allergies, diabetes) and behavior (e.g., attention, social interaction) problems. Some of the families will be followed up with additional questionnaires, as well as with genotyping and clinical interviews. The response frequency of the telephone interview is 80%. By November 2008, 7408 interviews had taken place. Types of samples * Saliva alt. EDTA whole blood * DNA Number of sample donors: 10 721 (June 2010)

Proper citation: CATSS - Child and Adolescent Twin Study in Sweden (RRID:SCR_005945) Copy   

•   Source: SciCrunch Registry
  

http://ki.se/ki/jsp/polopoly.jsp?d=29354&a=66742&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented on July 03, 2014. A study that is a follow-up of the CATSS study and includes 15-year old twins who have been identified with autism, ADHD, learning-, eating-, tics disorders, compulsion-, defiance-, conduct- or motor control problems. The study also includes the co-twin, controls and the parents. DNA will be collected from the twins and the parents. For the twins, both a saliva sample and capillary blood samples will be collected, and for the parents, a saliva sample will be collected. Types of samples * Saliva alt. capillary blood * DNA Number of sample donors: 764 (June 2010)

Proper citation: DOGSS (RRID:SCR_005946) Copy   

•   Source: SciCrunch Registry
  

https://ndriresource.org/for-researchers/services-capabilities-sample/htorr

NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program has been funded by the National Institutes of Health (NIH) for over 30 consecutive years to support research programs across multiple disciplines. It is through the HTORR program that NDRI provides academic biomedical investigators with donated normal and diseased human tissues and organs recovered from a diverse donor pool using customized procurement, processing, and preservation and distribution protocols. Our HTORR Program supports academic biomedical research investigators needs by providing: Access to a wide array of human biospecimens from any body system * Customized procurement in a variety of preservation formats including fresh, frozen, and fixed suitable for various analytical techniques * Reduced costs for tissue procurement * Technical support to design your studies utilizing human biospecimens * Letters of support and budgetary information for grant applications

Proper citation: Human Tissue and Organ for Research Resource (HTORR) (RRID:SCR_002859) Copy   

•   Source: SciCrunch Registry
  

http://www.sharmuk.org/

A not for profit organization to accelerate research into aging by sharing resources: providing access to cost and time effective, aged murine tissue through a biorepository and database of live ageing colonies, as well as promoting the networking of researchers and dissemination of knowledge through its online collaborative environment; MiCEPACE. ShARM will provide valuable resources for the scientific community while helping to reduce the number of animals used in vital research into aging. The biobank of tissue and networking facility will enable scientists to access shared research material and data. By making use of collective resources, the number of individual animals required in research experiments can be minimized. The project also has the added value of helping to reduce the costs of research by connecting scientists, pooling resource and combining knowledge. ShARM works in partnership with MRC Harwell and the Centre for Intergrated Research into Musculoskeletal Ageing (CIMA).

Proper citation: ShARM (RRID:SCR_003120) Copy   

•   Source: SciCrunch Registry
  

http://www.azcc.arizona.edu/research/shared-services/tacmass/tissue-acquisition

TACMASS collects, preserves, and banks biospecimens obtained from Arizona Cancer Center surgical patients who are seen by University Medical Center surgeons and oncologists. Biospecimens collected at the time of surgery include fresh surgical tissue, blood and urine. Serum, plasma and genomic DNA are harvested from the whole blood. AZCC Members and collaborators may request the use of banked biospecimens through TACMASS. The patient's surgeon or oncologist is responsible for consenting the patient for submission of surgical specimens to the AZCC BioRepository (IRB #06-0609-04, Setsuko Chambers, PI). The surgeon and the Department of Pathology attending physicians and residents are responsible for identifying appropriate tissue for banking that will not compromise pathological diagnosis. Tumor and/or normal adjacent tissue, identified by gross examination, that will not be needed for pathological diagnosis are preserved by fixing in formalin, snap freezing, and/or fixing in RNALater. Histological diagnosis is rendered on each piece of formalin-fixed and snap frozen tissue by Hematoxylin and Eosin staining (H&E). Everyone involved in submitting specimens to the Tumor Bank must maintain a current CITI Certification.

Proper citation: Arizona Cancer Center Tumor Bank (RRID:SCR_003544) Copy   

•   Source: SciCrunch Registry
  

http://www.lifesharing.org/index.php?option=com_content&view=article&id=5:tissue-bank&catid=4:tissue-bank&Itemid=6

Lifesharing Tissue Services provides the opportunity to improve and extend lives through the procurement, processing, storage and distribution of human tissue for transplantation and research. Originally established in 1984 to support the Burn Center at UCSD Medical Center, Lifesharing Tissue Services is a non-profit organization serving San Diego and Imperial counties in Southern California. The majority of tissues recovered by Lifesharing Tissue Services stay in this region to enable physicians to provide the best possible care for critically ill patients. Tissue grafting not only reduces pain and speeds recovery, but it also improves a patient''s quality of life. Fully accredited by the American Association of Tissue Banks (AATB) and the Food and Drug Administration (FDA), Lifesharing Tissue Services works to ensure the highest quality of tissue and technical service. Lifesharing is a member of the United Network for Organ Sharing (UNOS).

Proper citation: Lifesharing Tissue Services (RRID:SCR_004325) Copy   

•   Source: SciCrunch Registry
  

http://toc.lbg.ac.at/en/research-program/project-tumor-bank

As a basis for the experimental cluster projects, and for further future projects a collection of various biological specimens of cancer patients shall be established. All participating Ludwig Boltzmann Institutes (LBIs) are supplying biological specimens from tumor patients and clinical documentation. At the LBI for Gynecology and Gynecologic Oncology a tumor bank for biological specimens from gynecologic cancer patients already exists. All the procedures for sample processing and storage are well established. Existing equipment for storing tissue specimens at -196 degrees C can be used. Materials from the following malignant diseases are collected: Breast cancer Colorectal cancer Neuroendocrine tumors (NET) (Small cell lung cancer (SCLC) and Carcinoid tumors) Types of biological materials: Tissue (fresh frozen) Bone marrow Blood (serum/plasma/cell fractions) Pleural effusions Ascitic fluids Sputum Bronchial lavage Stool The biological specimens are initially processed at the respective LBIs or at their connected lab facilities. Enrichment of blood samples for disseminated tumor cells is done at the LBI for Gynecology and Gynecologic oncology. Long time storage of all materials is done at appropriate temperatures at the same institution. This LBI also coordinates the logistics. All relevant sample-specific and clinical data are surveyed at the respective LBIs and stored centralized in an on-line data bank in anonymized form, respecting all relevant regulations on data protection and security.

Proper citation: Ludwig Boltzman Tumour Bank (RRID:SCR_004322) Copy   

•   Source: SciCrunch Registry
  

http://www.promptprostate.com/

The MRC and Cancer Funders'' Forum (now National Cancer Research Institute, NCRI) established two cancer collaboratives in 2002, ProMPT and the Southern Collaborative. Their purpose was to increase the critical mass of basic and translational cancer researchers working on prostate cancer. The Collaboratives have both been successful in raising external grant income over the past 5 or 6 years and the current funding is very much geared around infrastructure to help with bio-marker development. This includes the establishment of biorepositories and tissue collections together with appropriate epidemiological and clinical information. The ProMPT collaborative is organized by Professor David Neal, Chair of Surgical Oncology in Cambridge. The other institutions include the Universities of Bristol, Manchester, Newcastle upon Tyne, Sheffield and York. The collaborative is very much working on translational aspects of prostate cancer research and has available to it a wide range of models. The Bristol group is working on epidemiological aspects and IGF, the Manchester group is working on stem cells, the Newcastle group is focused on target identification and validation and new drug development. Sheffield is working on model systems, bone metastasis and angiogenesis, York''s expertise is stem cells, structural biology and prostate specific gene targeting., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: ProMPT - Prostate Cancer Mechanisms of Progression and Treatment (RRID:SCR_004160) Copy   

•   Source: SciCrunch Registry
  

http://www.core.org/

The Center for Organ Recovery & Education (CORE) is one of 58 federally designated agencies in the United States known as a not-for-profit organ procurement organization (OPO). CORE is dedicated to promoting donation, education and research for the purpose of saving and improving the quality of life through organ, tissue and corneal transplantation. An innovative, responsive OPO, CORE plays a pivotal role between potential donors and patients awaiting transplantation. In addition to talking with families about the opportunity to donate, CORE coordinates the surgical recovery of organs, tissue and corneas, as well as the computerized matching of donated organs and placement of corneas. In 1995, CORE created the first donor card database in Pennsylvania. In 1996, the organization added tissue recovery and eye banking services to its organ recovery component. It enhanced its line of services by opening an internal laboratory in 1997, where CORE performs the necessary tests to help determine if the organs, tissue and corneas are healthy for transplantation. Since its inception more than 30 years ago, CORE has helped to provide more than 300,000 organs, tissue and corneas for transplantation. The chances for renewed health provided through CORE would not be possible without those who have said yes to donation.

Proper citation: Center for Organ Recovery and Education - CORE (RRID:SCR_004317) Copy   

•   Source: SciCrunch Registry